Ravichandran Venkataramani
Nessuna posizione attualmente
Storia della carriera di Ravichandran Venkataramani
Precedenti posizioni note di Ravichandran Venkataramani
Società | Posizione | Inizio | Fine |
---|---|---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Fondatore | 01/01/2015 | - |
Corporate Officer/Principal | 01/01/2015 | - | |
GENOCEA BIOSCIENCES, INC. | Corporate Officer/Principal | 01/07/2011 | - |
Formazione di Ravichandran Venkataramani
University of Wisconsin | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
GENOCEA BIOSCIENCES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |